Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval
Approved for use by diabetics to control blood sugar, liraglutide has also evidenced an ability to slow cognitive decline in a Phase 2b clinical trial, and reduce shrinkage of those areas of the brain ...
Lexaria Bioscience Corp.: Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval
Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B ...
healthday9d
Some GLP-1s Achieve More Weight Loss Than Others: Study
Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...
Novo Nordisk seeks to block compounded Victoza
Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
FiercePharma13d
Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing row
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
T-Net17d
Lexaria Bioscience Engages Contract Research Organization for Human Pilot Study Evaluating Liraglutide Processed with DehydraTECH
Liraglutide is currently sold only in an injectable form under the brand names Saxenda® and Victoza®, both manufactured by Novo Nordisk. Despite the launch of a genericized version of liraglutide by ...
healthday21d
FDA Approves First Generic Liraglutide Once-Daily Injection
THURSDAY, Dec. 26, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 ...
조선일보21d
FDA approves generic Victoza, expects improved supply of obesity drug Saxenda
Liraglutide, which mimics GLP-1, was released in 2010 as Victoza, a diabetes treatment, and subsequently launched as Saxenda, an obesity treatment, in 2014. Denmark's Novo Nordisk also released ...
McKnight's Senior Living22d
FDA approves first generic liraglutide once-daily injection
(HealthDay News) — The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist ...
The Hill23d
FDA approves GLP-1 generic for Type 2 diabetes
The liraglutide injection, which is currently in shortage and sold under the brand name Victoza, will provide a low-cost option for those who need GLP-1 medications. “Generic drugs provide ...
Business Standard23d
Biocon share price jumps 5% on DCP nod for diabetes drug in European Union
Liraglutide, in the European Union (EU). The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management. In an exchange filing, ...